FDA, Penn make it personal
Executive Summary
FDA and the University of Pennsylvania sign a five-year memorandum of understanding aimed at advancing drug/device co-development, companion diagnostics, translational medicine and new clinical trial models, among other goals, FDA announces Sept. 9. The two hope to develop safer, more effective drugs, devices, and biologics targeted at individuals rather than broad populations, a growing focus for FDA and for industry. The agreement also facilitates exchanges between FDA personnel and Penn students and faculty, which could help FDA recruitment efforts
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.